Terence W Friedlander

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
  2. doi request reprint Targeting the androgen receptor
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, University of California, San Francisco, CA 94143, USA Electronic address
    Urol Clin North Am 39:453-64. 2012
  3. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
  4. doi request reprint Common structural and epigenetic changes in the genome of castration-resistant prostate cancer
    Terence W Friedlander
    Division on Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Cancer Res 72:616-25. 2012
  5. ncbi request reprint Novel hormonal approaches in prostate cancer
    Terence W Friedlander
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Curr Oncol Rep 11:227-34. 2009

Detail Information

Publications5

  1. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
    ..NDGA therapy lengthens median PSADT but does not induce significant PSA declines. Further study may require a placebo-control to determine if changes in PSADT are drug related...
  2. doi request reprint Targeting the androgen receptor
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, University of California, San Francisco, CA 94143, USA Electronic address
    Urol Clin North Am 39:453-64. 2012
    ....
  3. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
    ..In this study, the efficacy of depot octreotide acetate was prospectively evaluated in patients with CRPC...
  4. doi request reprint Common structural and epigenetic changes in the genome of castration-resistant prostate cancer
    Terence W Friedlander
    Division on Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Cancer Res 72:616-25. 2012
    ..Genes identified in this integrated genomic study point to new drug targets in CRPC, an incurable disease state which remains the chief therapeutic challenge...
  5. ncbi request reprint Novel hormonal approaches in prostate cancer
    Terence W Friedlander
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Curr Oncol Rep 11:227-34. 2009
    ....